FDA
-
-
-
-
-
-
-
Pulmatrix and Cullgen waive merger exclusivity clause
-
-
-
-
-
-
-
Pulmatrix and Cullgen Announce Proposed Merger
-
-
-
-
-
-
-
Pulmatrix (PULM) Stops the PUR1900 Phase 2B Study Patient Enrollment and Closes the Study
-
-
-
-
-
-
-
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society
-
-
-
-
-
-
-
Pulmatrix Issues Letter to Stockholders
-
-
-
-
-
-
-
Pulmatrix Provides a Pipeline and Business Update
-
-
-
-
-
-
-
Pre-Open Stock Movers 01/02: (PULM) (SAVA) (WATT) Higher; (DRRX) (SIG) Lower (more...)
-
335,176 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


